CD8A and cancer: We next tested the effects of BAY1082439 on different subtypes of T cells as we observed significant increased CD8+ T cells and decreased Tregs in cancer associated immune cells in vivo in BAY-I treated cohort (Supplementary Figure 4B and Supplementary Fig. 4D).